Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant mean » significant main (Expand Search), significant green (Expand Search), significant degs (Expand Search)
Showing 261 - 280 results of 21,342 for search '(( significant decrease decrease ) OR ( ((significant mean) OR (significant gap)) decrease ))', query time: 0.42s Refine Results
  1. 261
    Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each combination of drill system (MIPS and MONO) and drilling protocol (DP1-DP5).

    Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each... by Marsel Ganeyev (21453399)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 262
    Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons.

    Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons. by Sara Hijazi (21656615)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 263
    A prepubertal CD decreases fat mass accumulation and prevents lean mass loss in adulthood despite a chronic HFD in Sprague-Dawley male rats.

    A prepubertal CD decreases fat mass accumulation and prevents lean mass loss in adulthood despite a chronic HFD in Sprague-Dawley male rats. by Ana Aguilar-Lozano (20614619)

    Published 2025
    Save to List
    Saved in:
  4. 264
    The diagram shows the mean IC-volume of both sides as a function of age with the degree of hearing loss as defined in the methods from class 1 (normal to moderate in both ears) to class 5 (severe, > 80 dB in both ears) coded by differently colored symbols.

    The diagram shows the mean IC-volume of both sides as a function of age with the degree of hearing loss as defined in the methods from class 1 (normal to moderate in both ears) to... by Pingling Kwok (14896191)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 265
    Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment.

    Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 266
    Flowchart of patient selection in this study.

    Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 267
    Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment.

    Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 268
    Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment.

    Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 269
    Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole.

    Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 270
    S1 Data -

    S1 Data - by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 271
    Clinical course of patient no.

    Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 272
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  13. 273
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  14. 274
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  15. 275
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  16. 276
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  17. 277
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  18. 278
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  19. 279
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  20. 280
    Mean values and 95% confidence intervals for resting flow, arterial occlusion pressure (AOP), biological zero, reactive hyperemia (RHmax), and time to peak across the three conditions.

    Mean values and 95% confidence intervals for resting flow, arterial occlusion pressure (AOP), biological zero, reactive hyperemia (RHmax), and time to peak across the three conditi... by Robert Trybulski (10998702)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: